Trending...
- Bruce C. Barnes Joins Summit's Board of Advisors
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
SAN DIEGO & LORDSTOWN, Ohio--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Kadmon Holdings, Inc. (NASDAQ: KDMN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 1, 2020 and March 10, 2021. Kadmon is a biopharmaceutical company that develops small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Kadmon's lead product candidate includes belumosudil (KD025), which is in Phase II clinical development for the treatment of chronic graft-versus-host disease ("cGVHD").
If you suffered a loss due to Kadmon Holdings, Inc.'s misconduct, click here.
Kadmon Holdings, Inc. (KDMN) Misled Investors Regarding its New Drug Submission for its Lead Drug Candidate
More on Ohio Pen
According to the complaint, on September 30, 2020, Kadmon announced the submission of a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD with the U.S. Drug and Food Administration ("FDA"). On November 30, 2020, Kadmon announced the FDA's acceptance of the NDA and that the FDA had assigned the NDA a Prescription Drug User Fee Act [PDUFA] target date of May 30, 2021. Throughout the class period, Kadmon touted the drug's trial milestones and efficacy. However, the Company failed to disclose that the NDA was incomplete and/or deficient when submitted and the additional data submitted in support of the NDA materially altered the initial submission, and therefore, the PDUFA target date.
On March 10, 2021, Kadmon announced that the FDA "has extended the review period" for the NDA and that, "[i]n a notice received from the FDA on March 9, 2021, the Company was informed that the [PDUFA] goal date for its Priority Review of belumosudil has been extended to August 30, 2021." Kadmon advised investors that "[t]he FDA extended the PDUFA date to allow time to review additional information submitted by Kadmon in response to a recent FDA information request," and that "[t]he submission of the additional information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA date by three months." On this news, Kadmon's stock price fell $0.52 per share, or 10.57%, to close at $4.40 per share on March 11, 2021. The stock continues to decline.
More on Ohio Pen
If you purchased shares of Kadmon Holdings, Inc. (KDMN) between October 1, 2020 and March 10, 2021, you have until June 2, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kadmon Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
If you suffered a loss due to Kadmon Holdings, Inc.'s misconduct, click here.
Kadmon Holdings, Inc. (KDMN) Misled Investors Regarding its New Drug Submission for its Lead Drug Candidate
More on Ohio Pen
- Kaltra unveils reversible microchannel coils – engineered for modern heat pumps
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
According to the complaint, on September 30, 2020, Kadmon announced the submission of a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD with the U.S. Drug and Food Administration ("FDA"). On November 30, 2020, Kadmon announced the FDA's acceptance of the NDA and that the FDA had assigned the NDA a Prescription Drug User Fee Act [PDUFA] target date of May 30, 2021. Throughout the class period, Kadmon touted the drug's trial milestones and efficacy. However, the Company failed to disclose that the NDA was incomplete and/or deficient when submitted and the additional data submitted in support of the NDA materially altered the initial submission, and therefore, the PDUFA target date.
On March 10, 2021, Kadmon announced that the FDA "has extended the review period" for the NDA and that, "[i]n a notice received from the FDA on March 9, 2021, the Company was informed that the [PDUFA] goal date for its Priority Review of belumosudil has been extended to August 30, 2021." Kadmon advised investors that "[t]he FDA extended the PDUFA date to allow time to review additional information submitted by Kadmon in response to a recent FDA information request," and that "[t]he submission of the additional information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA date by three months." On this news, Kadmon's stock price fell $0.52 per share, or 10.57%, to close at $4.40 per share on March 11, 2021. The stock continues to decline.
More on Ohio Pen
- Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
- Lokal Media House Earns ServiceTitan Certified Marketer Status
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- XRP fever is coming again, WOA Crypto helps the new trend and earns tens of thousands of dollars a day
If you purchased shares of Kadmon Holdings, Inc. (KDMN) between October 1, 2020 and March 10, 2021, you have until June 2, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kadmon Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Research Defense Examines Violence, Illiteracy, Non-Active Fathers, and Low Self-Esteem Among Males
- Investing in Greece: Your Definitive Real-Estate FAQ Guide
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- Advancing Circular Economy in Automotive ESD Packaging
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge
- Bruce C. Barnes Joins Summit's Board of Advisors